A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Completed · Phase 1, Phase 2 · NCT04393298
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $64,892
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 93
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- ginisortamab (drug), trifluridine/tipiracil (drug), mFOLFOX6 (drug)
- Dates
- Started 2020-07-09; completion 2024-04-11
- Results posted
- Yes
The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.
From ClinicalTrials.gov, last updated 2025-05-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $64,892 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lena Heung Infectious Disease · West Hollywood, CA
- Toros A. Dincman, MD, PHD Medical Oncology · Charleston, SC
- Kanwal P. Raghav, M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $33,107
- University of Southern California $16,569
- Medical Univ. of S. Carolina $15,217
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.